Sporadic case reports are congruous with the promising data of CD123- and CD33-directed CAR T-cell therapy in pre-clinical models [93,95,96], with more than 20 clinical trials ongoing [97], and we listed all phase II/III CAR T-cell trials containing adult r/r acute myeloid leukemia (AML) in Table 2. This evidence concerns the gene CD33 and acute myeloid leukemia.